Time to Reconsider Pacira Pharmaceuticals Inc (NASDAQ:PCRX) After More Short Sellers?

August 9, 2018 - By Jason Dias

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Logo

Investors sentiment decreased to 0.93 in 2018 Q1. Its down 0.47, from 1.4 in 2017Q4. It fall, as 32 investors sold Pacira Pharmaceuticals, Inc. shares while 51 reduced holdings. 28 funds opened positions while 49 raised stakes. 41.78 million shares or 4.29% more from 40.06 million shares in 2017Q4 were reported.
Wells Fargo Company Mn reported 165,673 shares stake. Td Asset Mgmt Incorporated holds 29,100 shares. State Of Wisconsin Inv Board has 39,400 shares. Healthcor Management Limited Partnership accumulated 2.44% or 2.30 million shares. Clearbridge Lc holds 1.09M shares or 0.03% of its portfolio. Baillie Gifford And owns 510,097 shares. Moreover, California Pub Employees Retirement Systems has 0% invested in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) for 65,000 shares. Creative Planning, a Kansas-based fund reported 9,050 shares. 270 are held by Advisory Svcs Ltd Liability Co. Vantage Limited, Pennsylvania-based fund reported 240 shares. 325,871 are owned by Rice Hall James & Assocs Lc. New York State Common Retirement Fund has 0.01% invested in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). Principal Fincl Grp Inc Inc holds 0% or 7,250 shares. Partner Investment Mgmt Lp accumulated 23,798 shares. Granahan Investment Management Ma invested 0.38% in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX).

Since May 15, 2018, it had 0 buys, and 8 selling transactions for $1.71 million activity. 373 shares valued at $12,316 were sold by Weiland Robert J. on Monday, June 4. $26,137 worth of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) was sold by HASTINGS PAUL J. Riker Lauren Bullaro had sold 801 shares worth $26,449. The insider Williams Kristen Marie sold 2,040 shares worth $67,361. The insider Reinhart Charles A. III sold $23,378. Scranton Richard sold $45,138 worth of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) on Monday, June 4.

The stock of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) registered an increase of 0.01% in short interest. PCRX’s total short interest was 4.90 million shares in August as published by FINRA. Its up 0.01% from 4.90 million shares, reported previously. With 696,000 shares average volume, it will take short sellers 7 days to cover their PCRX’s short positions. The short interest to Pacira Pharmaceuticals Inc’s float is 12.94%.

The stock increased 0.22% or $0.1 during the last trading session, reaching $45.2. About 405,724 shares traded. Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) has declined 23.22% since August 9, 2017 and is downtrending. It has underperformed by 35.79% the S&P500.

Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, makes, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. The company has market cap of $1.85 billion. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. It currently has negative earnings. The companyÂ’s lead product includes, EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia.

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Ratings Coverage

Among 14 analysts covering Pacira Pharmaceuticals (NASDAQ:PCRX), 8 have Buy rating, 1 Sell and 5 Hold. Therefore 57% are positive. Pacira Pharmaceuticals had 30 analyst reports since February 13, 2018 according to SRatingsIntel. The firm has “Buy” rating by Piper Jaffray given on Wednesday, February 28. The company was maintained on Tuesday, February 13 by Piper Jaffray. The firm has “Hold” rating by Canaccord Genuity given on Monday, April 9. JP Morgan maintained Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) on Tuesday, April 10 with “Neutral” rating. Mizuho maintained Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) on Tuesday, May 29 with “Hold” rating. The stock of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) has “Buy” rating given on Thursday, March 1 by H.C. Wainwright. The firm has “Overweight” rating by Barclays Capital given on Monday, August 6. The rating was maintained by Mizuho with “Hold” on Thursday, May 3. Wedbush maintained Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) rating on Thursday, April 5. Wedbush has “Buy” rating and $7200 target. The stock of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) has “Sell” rating given on Thursday, June 21 by Janney Capital.

More notable recent Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) news were published by: Seekingalpha.com which released: “Pacira Pharmaceuticals (PCRX) Q2 2018 Results – Earnings Call Transcript” on August 02, 2018, also Benzinga.com with their article: “The Daily Biotech Pulse: Denali’s Parkinson’s Candidate Clears Early-Stage Trials, Dexcom’s Strong Quarter” published on August 02, 2018, Seekingalpha.com published: “Premarket analyst action – healthcare” on August 06, 2018. More interesting news about Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) were released by: Nasdaq.com and their article: “Pacira to Report Second Quarter 2018 Financial Results on Thursday August 2, 2018” published on July 25, 2018 as well as Fool.com‘s news article titled: “Why Pacira Pharmaceuticals Stock Is on the Rise Today” with publication date: July 26, 2018.

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.